Dr. Whitehead was awarded a NIH R35 MIRA grant (R35GM153221) to develop rare heterocyles to understand pathogen metabolism, while Dr. Stamatikos was awarded a NIH R01 (R01HL175166) to identify novel atheroprotective mechanisms. Both were Research Project Leaders on the Phase 2 EPIC COBRE, and we look forward to their future successes. Congratulations Dan and Alexis!